DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Xellia
Xellia
1 Civica Rx and Xellia Pharmaceuticals Join Forces To
3746 Xellia 2015 Annual Report AW
Corporate Report 2015 CONTENTS
Xellia Pharmaceuticals, Aps Advisory Committee Background Document
Xellia Pharmaceuticals
Xellia Corporate Introduction
Vancomycin Xellia 500 Mg and 1000 Mg Powder for Solution for Infusion
Safety and Effectiveness of Bacitracin for IM Injection
Polymyxin B for Injection, USP500,000 Units/Vial
Polymyxin B-Induced Kidney Injury Assessment of a Novel Formulation of Polymyxin B (VRP-034) in Rats
Efficacy of a Fixed Combination of Tetracycline, Chloramphenicol, and Colistimethate Sodium for Treatment of Candida Albicans Ke
Corporate Report 2018 Contents
3746 Xellia 2017 Corporate Report AW.Indd
Vetropolycin® HC (Neomycin and Polymyxin B Sulfates
Tigecycline for Injection Tigecycline for Injection
These Highlights Do Not Include All the Information Needed to Use TIGECYCLINE for INJECTION, Safely and Effectively
Corporate Report 2019 Enhancing Patient Care and Improving Convenience Highlights Business Corporate Corporate Overview Responsibility Governance
Bacitracin for Injection, USP
Top View
VANCOMYCIN PIL NEW 13 27 9 2018.Indd
Corporate Report 2014
Polymyxin PIL 11.Indd
Bacitracin for Injection
Xellia Pharmaceuticals
Xellia Pharmaceuticals
Corporate Report 2020 Strengthening Supply During Unprecedented Times Highlights Business Sustainability Corporate Overview Governance